Colorectal cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 14,795 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

No stopped trial with a stated reason in this view.

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

  NCT05379595· Janssen Research & Development, LLC· Source

• RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer

  NCT07735624· Dana-Farber Cancer Institute· Source

• A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

  NCT06662786· Janssen Research & Development, LLC· Source

• Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

  NCT02484404· National Cancer Institute (NCI)· Source

• Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

  NCT04847063· National Cancer Institute (NCI)· Source

• A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

  NCT06663319· Janssen Research & Development, LLC· Source

• CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer

  NCT06730100· National Cancer Institute (NCI)· Source

• A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

  NCT06750094· Janssen Research & Development, LLC· Source

• Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy

  NCT07715903· National Cancer Institute (NCI)· Source

• Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

  NCT03190941· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 131
• Organoids 107
• Mendelian Randomization Analysis 49
• CRISPR-Cas Systems 34
• Gene Expression Profiling 331
• Sequence Analysis, RNA 29
• Whole Genome Sequencing 21
• Exome Sequencing 26
• Proteomics 101
• Metabolomics 91
• Mass Spectrometry 42
• Flow Cytometry 113
• Immunohistochemistry 207
• Liquid Biopsy 36
• Circulating Tumor DNA 117
• Xenograft Model Antitumor Assays 429
• Positron-Emission Tomography 38
• Magnetic Resonance Imaging 195
• Machine Learning 209
• Deep Learning 141
• Cohort Studies 313
• Genome-Wide Association Study 65

See which targets of this disease your abstract mentions, and go to the people working on them.